Raymond James Begins Coverage on LENZ Therapeutics (NASDAQ:LENZ)
Raymond James began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued an outperform rating and a $37.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. HC Wainwright began coverage on LENZ Therapeutics […]
30 Sep 07:04 · The Markets Daily